Chemotherapy (osteosarcoma) |
Silica nanoparticles |
Cancer cell membrane, ICG |
|
[229] |
Poly (ester amide) nanoparticles |
Apatinib |
|
[230] |
Silver nanoparticles |
Rhizophora apiculate, Ag |
|
[231] |
Polydopamine nanoparticles |
Paclitaxel, alendronate |
-
•
keep stable in PBS (pH 7.4), 5% glucose, plasma
-
•
display sustained drug release behavior
-
•
have stronger cytotoxicity against K7M2 wt osteosarcoma cells
|
[232] |
Liposomes |
hyaluronic acid, H2S-releasing doxorubicin |
-
•
deliver the drug within the endoplasmic reticulum (ER), inducing protein sulfhydration and ubiquitination
-
•
activate an ER stress pro-apoptotic response mediated by CHOP
|
[233] |
Dendrimers |
Platinum, carboxyl- |
|
[234] |
Mesoporous silica nanoparticles |
Doxorubicin, lectin |
|
[235] |
Platinum Nanoparticles |
Doxorubicin, |
|
[236] |
Chitosan |
Methotrexate, poloxamer |
|
[237] |
Chemotherapy (cancer bone metastasis) |
Liposomes |
Doxorubicin, Asp8, folate |
|
[238] |
Nanoscale metal-organic frameworks |
Calcium zoledronate |
|
[239] |
Micelles |
Alendronate, docetaxel |
-
•
exhibit the recruitment, differentiation and resorption activity of osteoclasts
-
•
attenuate the tumorigenesis and improve animal lifespan
|
[240] |
Quantum dots |
Doxorubicin, alendronate, Ag2S |
-
•
ensure the long circulation time of the nanodrugs
-
•
exhibit high affinity to the bone tissue
-
•
facilitate the on-site killing of cancer cells and minimize toxicity to normal tissue
-
•
provide a facile real-time feedback on the tumor growth and therapeutic efficacy via bioluminescence
|
[241] |
NaxWO3 nanoparticles |
oxygen vacancy-rich tungsten bronze |
|
[242] |
PAMAM dendrimers |
Docetaxel, hyaluronic acid, alendronate |
-
•
show osteoclasts and tumor cells dual-targeting ability
-
•
endocytosis by the tumor cells via CD44 receptor
-
•
inhibit the activity of osteoclasts
|
[243] |
Polymeric nanoparticles |
Paclitaxel, folic acid, alendronate |
-
•
exhibit high affinity for bone tissue
-
•
promote uptake by folate receptor-overexpressing cancer cells to augment PTX cytotoxicity
-
•
improve the survival rate of treated mice
|
[244] |
Gene Therapy |
Dendrimers |
miR-34a, miR-93, miR-200c |
|
[245] |
Nanodiamonds |
EWS-Fli-1 siRNA |
|
[246] |
Lipopolymer |
CRISPR/Cas9 plasmids |
-
•
facilitate selective distribution of CRISPR/Cas9 in both orthotopic OS and lung metastasis
-
•
enhance effective VEGFA genome editing in tumor
-
•
reduce angiogenesis and bone lesion with no detectable toxicity
|
[247] |
Scaffolds for bone regeneration |
Graphene oxide nanosheets |
Tricalcium silicate |
-
•
exhibit excellent photothermal performance with the irradiation of NIR
-
•
inhibit the growth of subcutaneous tumor tissue
-
•
promote cell proliferation and the ALP activity of MC3T3-E1
|
[248] |
Metal-organic framework nanosheets |
β-tricalcium phosphate, Cu ions |
-
•
kill osteosarcoma cells through released heat energy after exposure to NIR light (1.0 W cm−2, 10 min)
-
•
support the attachments of HBMSCs and HUVECs
-
•
stimulate osteogenesis and angiogenesis
|
[249] |
Chitosan scaffolds |
SrFe12O19, CaSiO3, doxorubicin |
|
[250] |
CuFeSe2 nanocrystals |
Bioactive glass |
-
•
endow scaffolds excellent photothermal performance
-
•
ablate the bone tumor cells (Saos-2 cells) and inhibit bone tumor growth
-
•
stimulate osteogenic gene expressions
|
[251] |